Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS >= 1% (LEAP-007): A phase III, randomized, double-blind study Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Yang, J. C-H.; Luft, A.; De la Mora Jimenez, E.; Lee, J. S.; Koralewski, P.; Karadurmus, N.; Sugawara, S.; Livi, L.; Basappa, N. S.; Quantin, X.; Dudnik, J.; Moran Ortiz, D.; Mekhail, T.; Okpara, C. E.; Zimmer, Z.; Samkari, A.; Bhagwati, N.; Csoszi, T.

authors

Publication Date

  • December 1, 2021

webpage

published in

category

start page

  • S1429

end page

  • S1430

volume

  • 32